{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:34:11Z","timestamp":1778571251198,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:00:00Z","timestamp":1292976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> European regulations require testing of manufacturing plasma for parvovirus B19 (B19) DNA to limit the load of this virus to a maximum acceptable level of 10 IU\/\u00b5L. To meet this requirement, most manufacturers introduced a test algorithm to identify and eliminate high\u2010load donations before making large manufacturing pools of plasma units. Sanquin screens all donations using a commercial assay from Roche and an in\u2010house assay.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Between 2006 and 2009, 6.2 million donations were screened using two different polymerase chain reaction (PCR) assays targeting B19 DNA. Donations with B19 DNA loads of greater than 1\u2003\u00d7\u200310<jats:sup>6<\/jats:sup> IU\/mL showing significant differences in viral load between the two assays were further analyzed by sequencing analysis.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> A total of 396 donations with B19 DNA loads of greater than 1\u2003\u00d7\u200310<jats:sup>6<\/jats:sup> IU\/mL were identified. Fifteen samples (3.8%) had discordant test results; 10 samples (2.5%) were underquantified by the Roche assay, two samples (0.5%) were underquantified by the in\u2010house assay, and three samples (0.8%) were not detected by the Roche assay. Sequencing analysis revealed mismatches in primer and probe\u2010binding regions. Phylogenetic analysis showed that 12 samples were B19 Genotype 1. The three samples not detected by the Roche assay were B19 Genotype 2.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> This study shows that 3.8% of the viremic B19 DNA\u2013positive donations are not quantified correctly by the Roche or in\u2010house B19 DNA assays. B19 Genotype 1 isolates showing incorrect test results are more common than B19 Genotype 2 or 3 isolates. Newly designed B19 PCR assays for blood screening should preferably have multiplexed formats targeting multiple regions of the B19 genome.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2010.02995.x","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T22:23:58Z","timestamp":1293056638000},"page":"1346-1354","source":"Crossref","is-referenced-by-count":24,"title":["Real\u2010time polymerase chain reaction detection of parvovirus B19 DNA in blood donations using a commercial and an in\u2010house assay"],"prefix":"10.1111","volume":"51","author":[{"given":"M.H.G.M.","family":"Koppelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"van Swieten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.T.M.","family":"Cuijpers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"Anonymous.Human anti\u2010D immunoglobulin monograph 0557 (since 1\/1\/2004); Human anti\u2010D immunoglobulin for intravenous administration monograph 1527 (since 1\/1\/2004); Human plasma (pooled and treated for virus inactivation) monograph 1646 (since 1\/7\/2004).2008. Ph.Europe 6thed. Strasbourg France: Council of Europe."},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0041-1132.2004.00610.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-77-11-2767"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.18.9124-9134.2002"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1585"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82037-0"},{"key":"e_1_2_8_8_2","first-page":"360","volume-title":"Virus taxonomy: eighth report of the international committee on taxonomy of viruses (ICTV)","author":"Fauquet CM","year":"2005"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.7.3666-3669.2006"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2007.00957.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01170.x"},{"key":"e_1_2_8_12_2","unstructured":"NublingM BuchheitK\u2010H.Results from recent EDQM\/OMCL PTS studies (PTS052 and PTS064) on B19 DNA NAT testing of plasma pools. Presentation at the SoGAT meeting June 14 2006 Bern Switzerland;2006."},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2004.05.011"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.28.3.495-503.1990"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gnh046"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01288.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2007.00956.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02160.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2007.00992.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.22.14197-14206.2005"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.22.12169-12178.2004"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00610-09"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01201-09"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01219.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.7.2408-2419.2002"},{"key":"e_1_2_8_27_2","unstructured":"PEI Bekanntmachungen im Bundesanzeiger.Abwehr von Arzneimittelrisiken. Anordnung von Auflagen zu den Zulassungen fur zellulare Blutkomponenten und gefrorenen Frischplasmen (vom 15. September 2008);2008."}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2010.02995.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2010.02995.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T16:03:02Z","timestamp":1697299382000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2010.02995.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1111\/j.1537-2995.2010.02995.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2010.02995.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,22]]}}}